Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Doxorubicin and Dacarbazine (AD) Regimen for Soft Tissue Sarcomas.

Literature DB >> 26405307

Doxorubicin and Dacarbazine (AD) Regimen for Soft Tissue Sarcomas.

Kyle E Adkins¹, Dominic A Solimando¹, J Aubrey Waddell¹.

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities: Chemical Disease

Year: 2015 PMID： 26405307 PMCID： PMC4567187 DOI： 10.1310/hpj5003-194

Source DB: PubMed Journal: Hosp Pharm ISSN： 0018-5787

Keyword Cloud
References

17 in total

1. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544

2. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications.

Authors: Olga Geling; Hans-Georg Eichler
Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544

Review 3. Proposal for classifying the acute emetogenicity of cancer chemotherapy.

Authors: P J Hesketh; M G Kris; S M Grunberg; T Beck; J D Hainsworth; G Harker; M S Aapro; D Gandara; C M Lindley
Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544

4. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.

Authors: K Antman; J Crowley; S P Balcerzak; S E Rivkin; G R Weiss; A Elias; R B Natale; R M Cooper; B Barlogie; D L Trump
Journal: J Clin Oncol Date: 1993-07 Impact factor: 44.544

5. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.

Authors: M Zalupski; B Metch; S Balcerzak; W S Fletcher; R Chapman; J D Bonnet; G R Weiss; J Ryan; R S Benjamin; L H Baker
Journal: J Natl Cancer Inst Date: 1991-07-03 Impact factor: 13.506

Review 9. Hepatotoxicity of chemotherapy.

Authors: Justin Floyd; Irfan Mirza; Bradley Sachs; Michael C Perry
Journal: Semin Oncol Date: 2006-02 Impact factor: 4.929

Review 10. Prevention and management of antineoplastic-induced hypersensitivity reactions.

Authors: K M Zanotti; M Markman
Journal: Drug Saf Date: 2001 Impact factor: 5.228